RNA editing, epitranscriptomics, and processing in cancer progression
- PMID: 25455629
- PMCID: PMC4622672
- DOI: 10.4161/15384047.2014.987555
RNA editing, epitranscriptomics, and processing in cancer progression
Abstract
The transcriptome is extensively and dynamically regulated by a network of RNA modifying factors. RNA editing enzymes APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) and ADAR (adenosine deaminase, RNA-specific) irreversibly recode primary RNA sequences, whereas newly described methylases (writers) and de-methylases (erasers) dynamically alter RNA molecules in response to environmental conditions. RNA modifications can affect RNA splicing, nuclear-cytoplasmic transport, translation, and regulation of gene expression by RNA interference. In addition, tRNA base modifications, processing, and regulated cleavage have been shown to alter global patterns of mRNA translation in response to cellular stress pathways. Recent studies, some of which were discussed at this workshop, have rekindled interest in the emerging roles of RNA modifications in health and disease. On September 10th, 2014, the Division of Cancer Biology, NCI sponsored a workshop to explore the role of epitranscriptomic RNA modifications and tRNA processing in cancer progression. The workshop attendees spanned a scientific range including chemists, virologists, and RNA and cancer biologists. The goal of the workshop was to explore the interrelationships between RNA editing, epitranscriptomics, and RNA processing and the enzymatic pathways that regulate these activities in cancer initiation and progression. At the conclusion of the workshop, a general discussion focused on defining the major challenges and opportunities in this field, as well as identifying the tools, technologies, resources and community efforts required to accelerate research in this emerging area.
Keywords: ADAR; APOBEC; DNA mutations; RNA modification; editing; epitranscriptomic; methylation; tRNA.
References
-
- Li S, Mason CE. The pivotal regulatory landscape of RNA modifications. Ann Rev Genomics Hum Genet 2014; 15:127-50; PMID:24898039; http://dx.doi.org/10.1146/annurev-genom-090413-025405 - DOI - PubMed
-
- Avesson L, Barry G. The emerging role of RNA and DNA editing in cancer. Biochimica et Biophysica Acta 2014; 1845:308-16; PMID:24607277 - PubMed
-
- Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med 2011; 5(11):105; PMID:24289319; http://dx.doi.org/10.1186/gm508 - DOI - PMC - PubMed
-
- Harris RS. Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Med 2013; 5(9):87; PMID:24073723; http://dx.doi.org/10.1186/gm490 - DOI - PMC - PubMed
-
- Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. . Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149(5):979-93; PMID:22608084; http://dx.doi.org/10.1016/j.cell.2012.04.024 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials